Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
Century Therapeutics (NASDAQ: IPSC) is harnessing the power of adult stem cells to develop curative cell therapy products for cancer and autoimmune diseases that we believe will allow us to overcome the limitations of first-generation cell therapies. Our genetically engineered, iPSC-derived cell product candidates are designed to specifically target hematologic and solid tumor cancers, with a broadening application to autoimmune diseases. We are leveraging our expertise in cellular reprogramming, genetic engineering, and manufacturing to develop therapies with the potential to overcome many of the challenges inherent to cell therapy and provide a significant advantage over existing cell therapy technologies. We believe our commitment to developing off-the-shelf cell therapies will expand patient access and provide an unparalleled opportunity to advance the course of cancer and autoimmune disease care. For more information on Century Therapeutics please visit .PHILADELPHIA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune disease, today announced that members of the management team will participate in the following events at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024:
费城，2024年11月26日（环球新闻通讯）--世纪生物治疗公司（纳斯达克：IPSC），一家创新的生物技术公司，正在开发来源于诱导多能干细胞（iPSC）的细胞疗法，应用于免疫肿瘤学和自身免疫疾病，今日宣布管理团队成员将参加2024年12月4日星期三派杰投资第36届年度医疗会议的以下活动：
-
Autoimmune Disease Cell Therapy Panel: 3:00 PM ET
- Presenter: Chad Cowan, Ph.D., Chief Scientific Officer
-
Fireside Chat: 4:30 PM ET
- Presenters: Brent Pfeiffenberger, Pharm.D., Chief Executive Officer, and Chad Cowan, Ph.D., Chief Scientific Officer
- 自身免疫疾病细胞疗法小组：东部时间下午3点
- 演讲者：查德·考恩，博士，首席科学官
- 炉边谈话：东部时间下午4点30分
- 演讲者：布伦特·普费芬伯格，药学博士，首席执行官，和查德·考恩，博士，首席科学官
A live webcast of the fireside chat can be accessed on the "Events & Presentations" page in the "Investors" section of the Company's website at . A replay of the webcast will be available for 90 days following the event.
可以在公司网站的“投资者”部分的“活动与演示”页面访问炉边谈话的直播网络广播。活动结束后，网络广播将可供观看90天。
About Century Therapeutics
关于百年细胞
Century Therapeutics (NASDAQ: IPSC) is harnessing the power of adult stem cells to develop curative cell therapy products for cancer and autoimmune diseases that we believe will allow us to overcome the limitations of first-generation cell therapies. Our genetically engineered, iPSC-derived cell product candidates are designed to specifically target hematologic and solid tumor cancers, with a broadening application to autoimmune diseases. We are leveraging our expertise in cellular reprogramming, genetic engineering, and manufacturing to develop therapies with the potential to overcome many of the challenges inherent to cell therapy and provide a significant advantage over existing cell therapy technologies. We believe our commitment to developing off-the-shelf cell therapies will expand patient access and provide an unparalleled opportunity to advance the course of cancer and autoimmune disease care. For more information on Century Therapeutics please visit .
Century Therapeutics（纳斯达克：IPSC）正在利用成人干细胞的力量开发治疗性细胞疗法产品，用于治疗癌症和自身免疫性疾病，我们相信这将帮助我们克服第一代细胞疗法的局限性。我们通过遗传工程和iPSC衍生细胞产品候选品的设计，专门针对血液系统和实体肿瘤癌症，扩展到自身免疫性疾病的广泛应用。我们利用我们在细胞重编程、遗传工程和制造领域的专业知识，开发具有潜力克服细胞治疗领域许多挑战的治疗方案，并比现有的细胞治疗技术具有重大优势。我们相信我们致力于开发现货细胞疗法将扩大患者的接触面，并为推进癌症和自身免疫性疾病治疗提供无与伦比的机会。如需了解更多有关Century Therapeutics的信息，请访问。
For More Information:
更多信息：
Investor Relations & Media Contacts
投资者关系和媒体联系
Century Therapeutics
Katja Buhrer
SVP, Head of Corporate Affairs and Strategy
katja.buhrer@centurytx.com
917-969-3438
世纪治疗
Katja Buhrer
企业事务与策略总监
katja.buhrer@centurytx.com
917-969-3438
Argot Partners
Noor Pahlavi
century@argotpartners.com
212-600-1902
阿哥特合伙人。
诺尔·帕赫拉维
century@argotpartners.com
212-600-1902
